Novel hemocyanin protein adjuvant for animal vaccine market.

Mikota Ltd与卡迪夫大学和皇家兽医学院合作（伦敦大学）正在评估一种新的蛋白佐剂作为疫苗递送平台，主要针对伴侣和牲畜市场。该项目是建立在Mikota早期的血蓝蛋白工作的基础上，在创造新的构建体，以解决研究表明伴侣动物和牲畜可能是潜在的无症状COVID-1。该项目的产出将证明Mikota的BioCyanin构建体在小鼠模型中作为疫苗佐剂的功效。这项工作将在未来的动物试验中扩大，预计将为未来在人类COVID-19疫苗或其他冠状病毒疫苗中的潜在用途提供证据。

Mikota Ltd in collaboration with Cardiff University and Royal Veterinary College (University of London) are evaluating a new protein adjuvant as a vaccine delivery platform, primarily aimed at the companion and livestock market.This project is building on Mikota's earlier hemocyanin work in creating novel constructs to address research demonstrating that companion animals and livestock may be potential asymptomatic COVID-19 carriers.The outputs from this project will demonstrate the efficacy of Mikota's BioCyanin constructs as a vaccine adjuvant in a mouse model. This work will be expanded in future animal trials which are expected to lead to evidence for potential future use in human COVID-19 vaccines, or other coronavirus vaccines.